serogroup


Also found in: Dictionary, Wikipedia.

serogroup

 [sēr´o-gro̳p]
1. a group of bacteria containing a common antigen, sometimes including more than one serotype, species, or genus. This is an unofficial designation, used in the classification of certain genera of bacteria, such as Leptospira, Salmonella, Shigella, and Streptococcus.
2. a group of viral species that are closely related antigenically.

se·ro·group

(sē'rō-grūp),
1. A group of bacteria containing a common antigen, used in the classification of certain genera of bacteria.
2. A group of viral species that are antigenically closely related.

serogroup

/se·ro·group/ (sēr´o-grldbomacp″) an unofficial designation denoting a group of bacteria containing a common antigen, possibly including more than one serotype, species, or genus.

serogroup

[sēr′o-gro̅o̅p]
1 a group of bacteria containing a common antigen, sometimes including more than one serotype, species, or genus. This is an unofficial designation, used in the classification of certain genera of bacteria, such as Leptospira, Salmonella, Shigella, and Streptococcus.
2 a group of viral species that are closely related antigenically.

se·ro·group

(sēr'ō-grūp)
1. A group of bacteria containing a common antigen, used in the classification of certain genera of bacteria.
2. A group of viral species that are antigenically closely related.
References in periodicals archive ?
pneumophila serogroup 1 in the foam and water tanks of both trucks and in the hose water sample and the smear from the tank of truck 1 (Table).
Despite the absence of serogroup B component in MCV4, declines in serogroup B disease were reported in addition to vaccine serogroups C and Y.
The ACIP Meningococcal Vaccines Work Group identified studies of the comparative immunogenicity, safety, and antibody persistence of 2- and 3-dose schedules of MenB-FHbp vaccine by consulting with the manufacturer and searching PubMed using the search terms "meningococcal serogroup B vaccine," "Trumenba," and "MenB-FHbp.
Children have been vaccinated through the National Immunisation Programme for meningococcal serogroup C since 2002.
These data, which were reviewed by the CHMP, demonstrate that the benefits of Trumenba are its ability to induce protective serum bactericidal antibody responses to diverse meningococcal serogroup B strains expressing fHBP variants that are representative of MenB strains causing invasive disease, and that TRUMENBA is a well-tolerated vaccine.
These data demonstrate that the benefits of TRUMENBA are its ability to induce protective serum bactericidal antibody responses to diverse meningococcal serogroup B strains expressing fHBP variants that are representative of MenB strains causing invasive disease and that TRUMENBA is a well-tolerated vaccine.
meningitidis is classified into 13 distinct serogroups; however, almost all invasive disease in humans is a result of infection with one of 6 serogroups.
The panel voted 14-1 in favor of a recommendation proposed by ACIP's meningococcal work group: The serogroup B meningococcal (MenB) vaccine series "may be administered to adolescents and young adults 16 through 23 years of age to provide short-term protection against most strains of serogroup B meningococcal disease," specifying that 16-18 years is "the preferred age for MenB vaccination.
The panel voted 14-1 in favor of the following recommendation proposed by ACIP's meningococcal work group: The serogroup B meningococcal (MenB) vaccine series "may be administered to adolescents and young adults 16 through 23 years of age to provide short-term protection against most strains of serogroup B meningococcal disease," specifying that 16-18 years is "the preferred age for MenB vaccination.
Serogroup status with corresponding MAT titre in vaccinated canine was assessed in 148 dog sera samples.
meningitidis serogroup B in people aged 10-25 years in the United States: Trumenba (Pfizer), licensed in October 2014, and Bexsero (Novartis Vaccines and Diagnostics), in January 2015.
The FDA has approved Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.